A Double-blind, Placebo-controlled, Parallel-group, Flexible-dose Study of Venlafaxine Extended-release Capsules in Adult Outpatients With Panic Disorder

Wyeth is now a wholly owned subsidiary of Pfizer0 sites343 target enrollmentApril 2001

ConditionsPanic Disorder

DrugsVenlafaxine ER

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Panic Disorder
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Enrollment: 343
Status: Completed
Last Updated: 16 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

The primary objective of this study is to determine the efficacy, safety, and tolerability of a flexible dose of venlafaxine extended-release (ER) capsules administered for 10 weeks in the treatment of adult outpatients with panic disorder (PD) in a placebo-controlled phase III study.

Registry

clinicaltrials.gov

Start Date

April 2001

End Date

December 2002

Last Updated

16 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Eligibility Criteria

Inclusion Criteria

•A male or female outpatient
•Be at least 18 years of age and legal age of consent
•Meet DSM-IV criteria for PD (with or without agoraphobia) for at least 3 months before study day 1

Exclusion Criteria

•Treatment with venlafaxine (IR or ER) within 6 months of study day 1
•Known hypersensitivity to venlafaxine (IR or ER) or related compounds
•History or presence of any clinically important hepatic, renal, or other medical disease that might compromise the study or be detrimental to the patient (eg, clinically important cardiac arrhythmia, unstable diabetes, carcinoma \[except basal cell epithelioma\], uncontrolled hypertension)